CompletedPhase 3

Clinical Evaluation of Arthrocentesis, Combination of Platelet-Rich Plasma and Cyclooxygenase Enzyme-2 Inhibitor in Treatment of Temporo-Mandibular Joint Anterior Displacement

Egypt20 participantsStarted 2023-12-01

Plain-language summary

Who can participate

Age range18 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients aged from 18 to 40 years old. * patients diagnosed with ID of TMJ, suffering from limited mandibular movements, joint pain and clicking. * Patients who are free from any systemic disease and controlled systemic disease (ASA I) (ASA II). * Patients willing to comply with the follow-up schedule and treatment protocol. * both genders are included Exclusion Criteria: * Patients with systemic diseases (ASA III, IV, V). * Patients who have myofascial pain dysfunction syndrome only. * Patients who have previous surgery in TMJ. * Patients who have previous arthrocentesis within 1 year. * Patients who received previous trauma to the joint. * Use of anticoagulants or immunosuppressive medications.

What they're measuring

Mandibular Movements: measured in millimeters using a ruler or digital caliper.

Timeframe: immediately, one, three and six months postoperatively

pain assessed by visual analogue scale

Timeframe: preoperatively, one, three and six months postoperatively

Joint Clicking: Evaluated using a stethoscope and recorded as either present or absent.

Timeframe: immediately, one, three, six months postoperatively

Trial details

NCT IDNCT07463404

SponsorSuez Canal University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Temporomandibular Joint Internal Derangement trials